degludec: latest news - GoINPHARMA
Wednesday, 16 January 2019 - 17:38

Degludec

Novo’s Tresiba approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for diabetes treatment. The product is a basal, new-generation insulin, to be taken once daily, that provides an ultra-long duration of action. Tresiba has…

FDA approves pediatric use of Novo’s Tresiba

Novo Nordisk announced that FDA has extended the use of Tresiba (degludec) to children one year of age and older. The product is a basal, long-acting insulin to be administered once-daily to patients with type 1 and type 2 diabetes,…

Tresiba, Novo Nordisk announces results from DEVOTE trial

Novo Nordisk announced the results from DEVOTE, a long-term, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba (degludec) vs glargine U100 when added to standard of care. More than 7,500 people with type 2 diabetes at…